Topic:

Clinical Trials

Latest Headlines

Latest Headlines

UPDATED: KaloBios tanks after scrapping another antibody following PhII flop

KB001-A, KaloBios Pharmaceuticals' antibody to treat lung infections in patients with cystic fibrosis, failed a Phase II study and is now joining the scrap heap started after KB003 failed Phase II for severe asthma last year.

Johnson & Johnson is third to bring Ebola vaccine to trials, but is it too late?

Johnson & Johnson started Phase I trials Tuesday for its Ebola vaccine, which its Janssen subsidiary developed in collaboration with Denmark's Bavarian Nordic. But does J&J's candidate come too late to catch up with its rivals and help combat the current epidemic?

Swiss trial of Merck/NewLink Ebola vaccine resumes at lower dose

The previously suspended Swiss trial of Merck and NewLink's experimental Ebola vaccine is back on, but this time at a lower dose.

Cempra shares soar on success of a head-to-head PhIII antibiotic study

Shares of Cempra shot up more than 30% in premarket trading on Monday as investors digested news of a promising outcome for its head-to-head study of its lead antibiotic solithromycin.

UPDATED: Achillion shares surge as hep C combo scores a quick 6-week cure

Shares of Achillion rocketed up Monday morning after the biotech reported that its NS5A drug combined with Gilead's Sovaldi scored a quick cure among a small group of hepatitis C patients after only 6 weeks of treatment.

Roche scuttles PhIII Alzheimer's study in yet another setback for the field

Yet another big Phase III test of an experimental Alzheimer's drug has flopped. And this time it's Roche's turn to admit defeat.

PPD partners up with ERT for data collection

PPD has signed a data-minded deal with the collection experts at ERT, a partnership the companies believe will help their clients conduct more efficient trials.

China green-lights domestic Ebola shot for clinical trials

China has approved a locally developed Ebola vaccine from its Academy of Military Medical Sciences for clinical trials, state news agency Xinhua said Thursday.

GSK shingles candidate hits its mark in hefty Phase III study

More than four years ago, GlaxoSmithKline began a Phase III study of a shingles candidate it hoped would eventually mount a challenge to Merck's Zostavax. Now, that candidate is one step closer after hitting its primary endpoint in that trial.

GlaxoSmithKline scores a PhIII success for marathon shingles vaccine study

GlaxoSmithKline got some good news for its big vaccines group, scoring a pivotal Phase III win for its shingles vaccine HZ/su more than four years after the study was launched.